Form 4: Bolt Biotherapeutics Director Acquires Stock Options
SEC Form 4 Filing
Jakob Dupont, a director of Bolt Biotherapeutics, acquired stock options for 20,000 shares at an exercise price of $0.351 on May 1, 2025.
Summary
- On May 1, 2025, Jakob Dupont, a director of Bolt Biotherapeutics, acquired stock options for 20,000 shares.
- The exercise price of these options is $0.351 per share.
- The options vest monthly over a period of time, with 1/6th of the shares vesting each month of continuous service starting May 1, 2025.
- The options expire on April 30, 2035.
- Following the transaction, Dupont directly owns derivative securities for 20,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard transaction filing, and while insider ownership can be a positive signal, this specific filing doesn't provide enough information to strongly skew positive or negative.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule indicates a long-term commitment from the director, as the options vest monthly over a period of time.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining investor confidence.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of the transaction: Jakob Dupont acquired stock options. |
| 05/01/2025 | Vesting start date: 1/6th of the shares will vest each month of continuous service. |
| 04/30/2035 | Expiration date of the stock options. |
Keywords
Stock Options, Form 4, Director, Bolt Biotherapeutics, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.